journal article·2024-01-23

Evaluation of Quatsome Morphology, Composition, and Stability for Pseudomonas aeruginosa Biofilm Eradication

Changyue Du, Sascha Woolcott, Alexander Sean Wahba, Sally R. Hamry, William L. Odette, Christopher J. Thibodeaux, Patrick Marchand, Janine Mauzeroll

Langmuir· Volume 40· Issue 3
Publisher page

Abstract

Biofilm infections are a major cause of food poisoning and hospital-acquired infections. Quaternary ammonium compounds are a group of effective disinfectants widely used in industry and households, yet their efficacy is lessened when used as antibiofilm agents compared to that against planktonic bacteria. It is therefore necessary to identify alternative formulations of quaternary ammonium compounds to achieve an effective biofilm dispersal. Quaternary ammonium amphiphiles can form vesicular structures termed “quatsomes” in the presence of cholesterol. In addition to their intrinsic antimicrobial properties, quatsomes can also be used for the delivery of other types of antibiotics or biomarkers. In this study, quatsomes were prepared from binary mixtures of cholesterol and mono- or dialkyl-quaternary ammonium compounds; then, the integrity and stability of their vesicular structure were assessed and related to monomer chain number and chain length. The quatsomes were used to treat Pseudomonas aeruginosa biofilms, showing effective antibiofilm abilities comparable to those of their monomers. A systematic liquid chromatography–mass spectrometry method for quantifying quatsome vesicle components was also developed and used to establish the significance of cholesterol in the quatsome self-assembly processes.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial agents and applications · Bacterial biofilms and quorum sensing · Antimicrobial Peptides and Activities

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, McGill University, Montreal, Quebec H3A 0B8, Canada

Sani-Marc Group, 42 Rue De L’Artisan, Victoriaville, Quebec G6P 7E3, Canada

Funding

Fonds de recherche du Qu?bec ? Nature et technologies · Natural Sciences and Engineering Research Council of Canada

References (69)

Show source-provided references
1. 10.1146/annurev.micro.54.1.4910.1146/annurev.micro.54.1.49 ↗
2. 10.1016/S0966-842X(00)01913-210.1016/S0966-842X(00)01913-2 ↗
3. Wingender J. · 1999 · 110.1007/978-3-642-60147-7 ↗
4. 10.1016/s0140-6736(01)05321-110.1016/s0140-6736(01)05321-1 ↗
5. 10.1021/la400380310.1021/la4003803 ↗
6. 10.1039/C4TB01953A10.1039/C4TB01953A ↗
7. 10.1016/j.nano.2019.10213610.1016/j.nano.2019.102136 ↗
8. 10.1002/adfm.20210351110.1002/adfm.202103511 ↗
9. 10.1021/acsami.2c1049710.1021/acsami.2c10497 ↗
10. 10.1002/smll.20210195910.1002/smll.202101959 ↗
11. 10.1021/acs.langmuir.7b0353910.1021/acs.langmuir.7b03539 ↗
12. 10.1039/C8NR07110A10.1039/C8NR07110A ↗
13. 10.1177/153537021989677910.1177/1535370219896779 ↗
14. 10.1111/j.1365-2672.2005.02664.x10.1111/j.1365-2672.2005.02664.x ↗
15. 10.1128/AEM.02633-1410.1128/AEM.02633-14 ↗
16. 10.1021/acsomega.7b0077910.1021/acsomega.7b00779 ↗
17. 10.1111/jam.1505310.1111/jam.15053 ↗
18. 10.1016/S0927-7757(98)00765-110.1016/S0927-7757(98)00765-1 ↗
19. 10.1016/j.job.2021.09.00210.1016/j.job.2021.09.002 ↗
20. 10.1021/acs.langmuir.2c0012810.1021/acs.langmuir.2c00128 ↗
21. 10.1002/smll.20170385110.1002/smll.201703851 ↗
22. 10.1021/acsami.0c0304010.1021/acsami.0c03040 ↗
23. 10.1016/0005-2736(83)90348-610.1016/0005-2736(83)90348-6 ↗
24. 10.1016/0003-2697(80)90269-910.1016/0003-2697(80)90269-9 ↗
25. 10.1021/i560136a00510.1021/i560136a005 ↗
26. 10.1016/0003-2670(94)00428-O10.1016/0003-2670(94)00428-O ↗
27. 10.1111/lam.1342910.1111/lam.13429 ↗
28. 10.1039/C5OB02480C10.1039/C5OB02480C ↗
29. 10.1080/1061027950802948010.1080/10610279508029480 ↗
30. 10.1126/science.173.3999.83610.1126/science.173.3999.836 ↗
31. 10.1016/j.jhin.2014.11.01910.1016/j.jhin.2014.11.019 ↗
32. 10.1038/s41592-019-0396-910.1038/s41592-019-0396-9 ↗
33. 10.1128/AAC.49.7.2612-2617.200510.1128/AAC.49.7.2612-2617.2005 ↗
34. 10.1128/AEM.02073-0710.1128/AEM.02073-07 ↗
35. 10.1080/00202967.2022.206683010.1080/00202967.2022.2066830 ↗
36. 10.1016/j.jconrel.2016.06.01710.1016/j.jconrel.2016.06.017 ↗
37. Regev O. · 1994 · 29810.1007/BFb0115187 ↗
38. 10.1021/jp990852p10.1021/jp990852p ↗
39. 10.1021/la902670610.1021/la9026706 ↗
40. 10.1021/ja00453a06610.1021/ja00453a066 ↗
41. 10.1021/j100372a06710.1021/j100372a067 ↗
42. 10.1021/la050701f10.1021/la050701f ↗
43. 10.1016/0304-4157(76)90008-310.1016/0304-4157(76)90008-3 ↗
44. 10.1007/s13346-015-0220-810.1007/s13346-015-0220-8 ↗
45. 10.1021/j100195a03310.1021/j100195a033 ↗
46. 10.1002/syst.20200004910.1002/syst.202000049 ↗
47. 10.1209/0295-5075/13/7/01510.1209/0295-5075/13/7/015 ↗
48. 10.1016/S0927-7757(00)00516-110.1016/S0927-7757(00)00516-1 ↗
49. 10.1080/0267829031000162855510.1080/02678290310001628555 ↗
50. 10.1021/la990831m10.1021/la990831m ↗
51. 10.1115/1.279603410.1115/1.2796034 ↗
52. 10.1194/jlr.M500506-JLR20010.1194/jlr.M500506-JLR200 ↗
53. 10.1016/j.jpba.2020.11364210.1016/j.jpba.2020.113642 ↗
54. 10.1007/978-1-0716-2954-3_2010.1007/978-1-0716-2954-3_20 ↗
55. 10.1046/j.1365-2672.1999.00770.x10.1046/j.1365-2672.1999.00770.x ↗
56. 10.1046/j.1365-2672.2002.01667.x10.1046/j.1365-2672.2002.01667.x ↗
57. 10.1039/C9EW01056D10.1039/C9EW01056D ↗
58. 10.1046/j.1365-2672.2003.02064.x10.1046/j.1365-2672.2003.02064.x ↗
59. 10.4265/bio.12.9310.4265/bio.12.93 ↗
60. 10.1128/AAC.00375-0610.1128/AAC.00375-06 ↗
61. 10.1248/jhs1956.40.34410.1248/jhs1956.40.344 ↗
62. 10.1093/jac/dkm38210.1093/jac/dkm382 ↗
63. 10.1021/jm00220a01010.1021/jm00220a010 ↗
64. 10.1016/j.copbio.2015.03.01810.1016/j.copbio.2015.03.018 ↗
65. 10.1371/journal.pone.013180610.1371/journal.pone.0131806 ↗
66. 10.2147/IJN.S33580410.2147/IJN.S335804 ↗
67. 10.1016/j.jconrel.2014.07.06110.1016/j.jconrel.2014.07.061 ↗
68. 10.3390/pharmaceutics802001810.3390/pharmaceutics8020018 ↗
69. 10.1080/08927014.2015.113451610.1080/08927014.2015.1134516 ↗